These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 22930158)
1. Optimisation of BACE1 inhibition of tripartite structures by modification of membrane anchors, spacers and pharmacophores - development of potential agents for the treatment of Alzheimer's disease. Linning P; Haussmann U; Beyer I; Weidlich S; Schieb H; Wiltfang J; Klafki HW; Knölker HJ Org Biomol Chem; 2012 Oct; 10(41):8216-35. PubMed ID: 22930158 [TBL] [Abstract][Full Text] [Related]
2. Triazole-linked reduced amide isosteres: an approach for the fragment-based drug discovery of anti-Alzheimer's BACE1 inhibitors. Monceaux CJ; Hirata-Fukae C; Lam PC; Totrov MM; Matsuoka Y; Carlier PR Bioorg Med Chem Lett; 2011 Jul; 21(13):3992-6. PubMed ID: 21621412 [TBL] [Abstract][Full Text] [Related]
3. Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story. Stamford A; Strickland C Curr Opin Chem Biol; 2013 Jun; 17(3):320-8. PubMed ID: 23683349 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of arylquinones as BACE1 inhibitors, β-amyloid peptide aggregation inhibitors, and destabilizers of preformed β-amyloid fibrils. Ortega A; Rincón Á; Jiménez-Aliaga KL; Bermejo-Bescós P; Martín-Aragón S; Molina MT; Csákÿ AG Bioorg Med Chem Lett; 2011 Apr; 21(8):2183-7. PubMed ID: 21441028 [TBL] [Abstract][Full Text] [Related]
5. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions. Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541 [TBL] [Abstract][Full Text] [Related]
6. Structural design, solid-phase synthesis and activity of membrane-anchored β-secretase inhibitors on Aβ generation from wild-type and Swedish-mutant APP. Schieb H; Weidlich S; Schlechtingen G; Linning P; Jennings G; Gruner M; Wiltfang J; Klafki HW; Knölker HJ Chemistry; 2010 Dec; 16(48):14412-23. PubMed ID: 21132705 [TBL] [Abstract][Full Text] [Related]
7. Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design. Hamada Y; Tagad HD; Nishimura Y; Ishiura S; Kiso Y Bioorg Med Chem Lett; 2012 Jan; 22(2):1130-5. PubMed ID: 22178553 [TBL] [Abstract][Full Text] [Related]
8. The potential for BACE1 inhibitors in the treatment of Alzheimer's disease. Hussain I IDrugs; 2004 Jul; 7(7):653-8. PubMed ID: 15243867 [TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice. Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745 [TBL] [Abstract][Full Text] [Related]
10. Tetrapeptides, as small-sized peptidic inhibitors; synthesis and their inhibitory activity against BACE1. Kakizawa T; Hidaka K; Hamada D; Yamaguchi R; Uemura T; Kitamura H; Tagad HD; Hamada T; Ziora Z; Hamada Y; Kimura T; Kiso Y J Pept Sci; 2010 Jun; 16(6):257-62. PubMed ID: 20474036 [TBL] [Abstract][Full Text] [Related]
14. Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor. Cumming JN; Smith EM; Wang L; Misiaszek J; Durkin J; Pan J; Iserloh U; Wu Y; Zhu Z; Strickland C; Voigt J; Chen X; Kennedy ME; Kuvelkar R; Hyde LA; Cox K; Favreau L; Czarniecki MF; Greenlee WJ; McKittrick BA; Parker EM; Stamford AW Bioorg Med Chem Lett; 2012 Apr; 22(7):2444-9. PubMed ID: 22390835 [TBL] [Abstract][Full Text] [Related]
15. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133 [TBL] [Abstract][Full Text] [Related]
16. Design of pentapeptidic BACE1 inhibitors with carboxylic acid bioisosteres at P1' and P4 positions. Tagad HD; Hamada Y; Nguyen JT; Hamada T; Abdel-Rahman H; Yamani A; Nagamine A; Ikari H; Igawa N; Hidaka K; Sohma Y; Kimura T; Kiso Y Bioorg Med Chem; 2010 May; 18(9):3175-86. PubMed ID: 20381362 [TBL] [Abstract][Full Text] [Related]
17. Progress toward the discovery and development of efficacious BACE inhibitors. Durham TB; Shepherd TA Curr Opin Drug Discov Devel; 2006 Nov; 9(6):776-91. PubMed ID: 17117686 [TBL] [Abstract][Full Text] [Related]
18. Alzheimer's disease. A firm base for drug development. De Strooper B; König G Nature; 1999 Dec; 402(6761):471-2. PubMed ID: 10591201 [No Abstract] [Full Text] [Related]
19. A stereoselective approach to peptidomimetic BACE1 inhibitors. Butini S; Gabellieri E; Brindisi M; Giovani S; Maramai S; Kshirsagar G; Guarino E; Brogi S; La Pietra V; Giustiniano M; Marinelli L; Novellino E; Campiani G; Cappelli A; Gemma S Eur J Med Chem; 2013; 70():233-47. PubMed ID: 24158015 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of quinazolinone-based hydrazones with potential use in Alzheimer's disease. Haghighijoo Z; Firuzi O; Hemmateenejad B; Emami S; Edraki N; Miri R Bioorg Chem; 2017 Oct; 74():126-133. PubMed ID: 28780149 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]